Short Interest in Iradimed Corporation (NASDAQ:IRMD) Grows By 22.0%

Iradimed Corporation (NASDAQ:IRMD) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 105,000 shares, an increase of 22.0% from the November 30th total of 86,100 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 39,100 shares, the short-interest ratio is presently 2.7 days.

Iradimed Stock Down 0.2 %

IRMD traded down $0.09 on Tuesday, reaching $55.00. The company had a trading volume of 21,902 shares, compared to its average volume of 48,247. Iradimed has a 1 year low of $40.18 and a 1 year high of $57.95. The stock has a market capitalization of $696.85 million, a PE ratio of 37.67 and a beta of 0.82. The stock has a 50-day moving average price of $53.38 and a 200-day moving average price of $48.86.

Iradimed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were given a $0.15 dividend. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.09%. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

Insider Buying and Selling

In other news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 37.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Huntington National Bank lifted its position in Iradimed by 51.3% during the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 504 shares during the period. Gladius Capital Management LP increased its stake in Iradimed by 126.6% in the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 965 shares during the period. Quantbot Technologies LP raised its position in Iradimed by 83.0% during the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Iradimed in the 3rd quarter worth $126,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Iradimed in the third quarter valued at about $147,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.